Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) have been assigned an average rating of “Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $40.50.

Several brokerages recently commented on PLRX. Leerink Partnrs raised shares of Pliant Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on Pliant Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $33.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Pliant Therapeutics in a report on Friday, November 8th.

Institutional Trading of Pliant Therapeutics

Several large investors have recently bought and sold shares of PLRX. Summit Securities Group LLC acquired a new position in Pliant Therapeutics in the 2nd quarter worth $59,000. Atria Investments Inc purchased a new stake in Pliant Therapeutics during the 3rd quarter worth approximately $112,000. Deerfield Management Company L.P. Series C acquired a new position in shares of Pliant Therapeutics in the 2nd quarter valued at approximately $126,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Pliant Therapeutics by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after buying an additional 4,607 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Pliant Therapeutics in the third quarter valued at $145,000. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Trading Up 1.1 %

NASDAQ PLRX opened at $13.49 on Monday. The company has a 50-day moving average of $14.02 and a 200-day moving average of $12.86. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26. Pliant Therapeutics has a 12 month low of $10.22 and a 12 month high of $19.62. The company has a market cap of $820.92 million, a P/E ratio of -4.04 and a beta of 1.05.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.